Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding

Hypertension Research

Volumn 20, Issue 2, 1997, Pages 61-73

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIHYDROPYRIDINE; DILTIAZEM; HYPERTENSIVE AGENT; NIFEDIPINE; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLEEDING; CANCER; CANCER RISK; COLON CANCER; CORONARY RISK; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; SHORT SURVEY; STROKE; WORLD HEALTH ORGANIZATION;

ADRENERGIC BETA-ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HEMORRHAGE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 0003177219     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.20.61     Document Type: Article

References (81)

1. Collins R, Peto R, Gray R, Parish S: Large-scale randomized evidence: trials and overviews, in Weatherall D, Ledingham J, Warrell D(eds): Oxford Textbook of Medicine. Third Edition. Oxford, Oxford University Press, 1996, 21-32.
2. Collins R, Gray R, Godwin J, Peto R: Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Meet 1987; 6: 245-250.
3. Bigger J, Fleiss J, Rolnitzky L, Merab J, Ferrick K: Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol 1985; 55: 623-630.
4. Yusuf S, Garg R, Smith T, et al: Which heart failure patients benefit the most from long-term digoxin therapy. Circulation 1996; 94: I-23.
5. Yusuf S, Furberg C, Wittes J, Bailey K: Digitalis - a new controversy regarding an old drug: the pitfalls of inappropriate methods. Circulation 1986; 73: 14-18.
6. Grady D, Rubin SM, Petitti DB, et al: Hormone replacement therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
7. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-839.
8. Collins R, MacMahon S: Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-298.
9. Antiplatelet Trialists Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331.
10. Antiplatelet Trialists Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. Part I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 71-72.
11. Thumer H, Lund-Larsen P, Tverdal A: Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study. J Hypertens 1994; 2: 481-490.
12. Paganini-Hill A, Chao A, Ross R, Henderson B: Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 1990; 300: 116-118.
13. Israili Z, Hall W: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
14. MacMahon S, Peto R, Cutler J, et al: Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
15. Flack J, Neaton J, Grimm R, et al, for the Multiple Risk Factor Intervention Trial Research Group: Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995; 92: 2437-2445.
16. Rodgers A, MacMahon S, Gamble G, Slattery J, Sandercock P, Warlow C, on behalf of the UKTIA Collaborative Group: Blood pressure and risk of stroke in patients with cerebrovascular disease. Br Med J 1996; 313: 147.
17. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
18. Lonn E, Yusuf S, Prabhat J, et al: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-2069.
19. Furberg C, Psaty B, Meyer J: Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
20. Furberg C, Psaty B: Corrections to the nifedipine meta-analysis. Circulation 1996; 93: 1475-1476.
21. Neaton JD, Grimm RH, Prineas RJ, et al: Treatment of Mild Hypertension Study. Final results. J Am Coll Cardiol 1993; 270: 713-724.
22. Materson B: Department of Veteran Affairs single drug therapy of hypertension: final results. Am J Hypertens 1993; 8: 189-192.
23. The GLANT Study Group: A 12-month comparison of ACE-inhibitor and Ca-antagonist therapy in mild to moderate essential hypertension - The GLANT Study. Hypertens Res 1995; 18: 235-244.
24. Borhani N, Mercuri M, Borhani P, et al: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785-791.
25. Gong L, Zhang W, Zhu Y, Zhu J, 11 collaborating centres in the Shanghai area, Kong D, et al: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-1245.
26. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial-II-DAVIT II). Am J Cardiol 1990; 66: 779-785.
27. Wilcox R, Hampton J, Banks D, et al: Trial of early nifedipine in acute myocardial infarction: the TRENT study. Br Med J 1986; 293: 1204-1208.
28. Held PH, Yusuf S, Furberg CD: Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989; 299: 1187-1192.
29. Yusuf S, Held P, Furberg C: Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295-1297.
30. Yusuf S: Verapamil following uncomplicated myocardial infarction: promising, but not proven. Am J Cardiol 1996; 77: 421-422.
31. Rengo F, Carbonin P, Pahor M, et al, and the CRIS Investigators: A controlled trial of verapamil in patients after acute myocardial infarction. Results of the Calcium Antagonist Reinfarction Italian Study-CRIS. Am J Cardiol 1995; 77: 365-369.
32. Glasser S, Clark P, Lipicky R, Hubbard J, Yusuf S: Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA 1991; 265: 1550-1554.
33. Dargie H, Ford I, Fox K, on behalf of the TIBET study group: Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17: 104-112.
34. Rehnqvist N, Hjemdahl P, Billing E, et al: Effects of metoprolol vs. verapamil in patients with stable angina pectoris. Eur Heart J 1996; 17: 76-81.
35. Cohn J, Ziesche S, Loss L, Anderson G, and the V-HeFT Study Group: Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT VIII. Circulation 1995; 92: I-143.
36. Packer M, O'Connor C, Ghali J, et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114.
37. Littler W, Sheridan D, on behalf of the UK Study Group: Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J 1995; 73: 428-433.
38. Psaty B, Heckbert S, Koepsell T, et al: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
39. Jick H, Derby L, Gurewich V, Vasilakis C: The risk of myocardial infarction in persons with uncomplicated essential hypertension associated with antihypertensive drug treatment. Pharmacotherapy 1996; 16: 321-326.
40. Aursnes I, Litleskare I, Froyland H, Abdelnoor M: Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Pressure 1995; 4: 157-163.
41. Alderman M, Cohen H, Roque R, Madhavan S: Long- and short-acting calcium antagonists differ with regard to cardiovascular outcomes in hypertensive patients. Lancet 1997; in press.
42. Mancia G, Van Zwieten P: How safe are calcium antagonists in hypertension and coronary heart disease? J Hypertens 1996; 14: 13-17.
43. Pahor M, Guralnik J, Corti M, Foley D, Carbonin P, Havlik R: Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1-7.
44. Koenig W, Lowel H, Lewis M, Hormann A: Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993. Eur Heart J 1996; 17: 1199-1206.
45. Braun S, Boyko V, Behar S, et al, on behalf of the Bezafibrate Infarction Prevention Study Participants: Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J Am Coll Cardiol 1996; 28: 7-11.
46. Abascal V, Larson M, Evans J, Poli K, Levy D: Calcium channel blocker use is not associated with increased mortality. Circulation 1996; 94: I-578.
47. Harriet P: Cancer and hypertension - an unresolved issue. Hypertension 1996; 28: 321-324.
48. Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S, Bianco A: Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 1991; 27: 1393-1395.
49. Pahor M, Guralnik J, Salive M, Corti M, Carbonin P, Havlik R: Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-699.
50. Pahor M, Guralnik J, Ferrucci L, et al: Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-497.
51. Connor J, Sawczuk I, Benson M, et al: Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988; 13: 119-130.
52. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 1993; 7: 453-463.
53. deBlois D, Tea B, Dam T, Hamet P: Increased smooth muscle cell apoptosis during regression of vascular hypertrophy in the aorta of spontaneously hypertensive rats. Hypertension 1997; 29 (Suppl 2): in press.
54. Ekbom A, Adama H: Kalciumantagonister och cancer - en oversikt. Inf Lakemedelsverket 1996; 7: 3-5.
55. Hardell L, Fredrikson M, Axelson O: Case control study on colon cancer regarding previous diseases and drug intake. Int J Oncol 1996; 8: 439-444.
56. Pahor M, Guralnik J, Furberg C, Carbonin P, Havlik R: Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-1065.
57. Wagenknecht L, Furberg C, Hammon J, Legault C, Troost B: Surgical bleeding: unexpected effect of a calcium antagonist. Br Med J 1995; 310: 776-777.
58. Pilotto A, Leandro G, Franceschi M, Di Mario F, Valerio G: Antagonism to calcium antagonists. Lancet 1996; 347: 1761-1762.
59. Grodecki-De Franco P, Steinhubl S, et al: Calcium antagonist use and perioperative bleeding complications: an analysis of 5,157 patients. Circulation 1996; 94: I-476.
60. Hynynen M, Kuitunen A, Salmenpera M: Surgical bleeding and calcium antagonists [letter, comment]. Br Med J 1996; 312: 313.
61. The Danish Study Group on Verapamil in Myocardial Infarction: Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516-528.
62. The Israeli SPRINT Study Group: Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988; 9: 354-364.
63. Multicenter Diltiazem Post-infarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-392.
64. Psaty BM, Sevick MA: Antagonism to calcium antagonists. Lancet 1996; 347: 1761.
65. Robinson M, Teasdale G: Calcium antagonists in the management of subarachnoid haemorrhage. Cerebrovascular and Brain Metabolism Reviews. New York, Raven Press Ltd, 1990, pp 205-226.
66. Pickard JD, Murray GD, Illingworth R, et al: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. Br Med J 1989; 298: 636-642.
67. Mohr JP, Orgogozo JM, Harrison MJG, et al: Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994; 4: 197-203.
68. Kaste M, Fogelholm R, Erila T, et al: A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994; 25: 1348-1353.
69. Takagawa Y, Shimamoto K, Masuda A, Iimura O: Survey of current drug therapy for elderly hypertension. Ther Res 1995; 16: 3822-3826.
70. Murros K, Furberg C: Calcium antagonists and extrapyramidal symptoms. Circulation 1996; 94: I-579.
71. Brown M: Calcium-channel blockers and cancer. Lancet 1996; 348: 1166.
72. Boston Collaborative Drug Surveillance Program: Reserpine and breast cancer. Lancet 1974; 2: 669-671.
73. Armstrong B, Stevens N, Doll R: Retrospective study of the association between use of Rauwolfia derivatives and breast cancer. Lancet 1974; 2: 672-674.
74. Heinonen O, Shapiro S, Tuominen L, Turunen M: Reserpine use in relation to breast cancer. Lancet 1974; 2: 675-677.
75. Horwitz R, Feinstein A: Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985; 145: 1873-1875.
76. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
77. SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 372: 685-691.
78. Walker A, Stampfer M: Observational studies of drug safety. Lancet 1996; 348: 489.
79. Buring J, Glynn R, Hennekens C: Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. JAMA 1995; 274: 654-655.
80. Easterbrook P, Berlin J, Gopalan R, Matthews D: Publication bias in clinical research. Lancet 1991; 337: 867-872.
81. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Coll Cardiol 1995; 273: 1450-1456.